Search Page

1

Cite

Share

Serotonin and hallucinogens.

Aghajanian GK, Marek GJ. Aghajanian GK, et al. Among authors: marek gj. Neuropsychopharmacology. 1999 Aug;21(2 Suppl):16S-23S. doi: 10.1016/S0893-133X(98)00135-3. Neuropsychopharmacology. 1999. PMID: 10432484 Review.

Cite

Share

2

Cite

Share

Translational medicine special issue.

Day M, Fox GB, Marek GJ. Day M, et al. Among authors: marek gj. Biochem Pharmacol. 2011 Jun 15;81(12):1353-5. doi: 10.1016/j.bcp.2011.01.018. Epub 2011 Feb 4. Biochem Pharmacol. 2011. PMID: 21296055 No abstract available.

Cite

Share

3

Cite

Share

Translating Pharmacology into Therapeutics to Fight the Opioid Crisis.

Marek GJ, Cunningham KA, Rasmussen K. Marek GJ, et al. J Pharmacol Exp Ther. 2019 Nov;371(2):394-395. doi: 10.1124/jpet.119.262477. J Pharmacol Exp Ther. 2019. PMID: 31628259 No abstract available.

Cite

Share

4

Cite

Share

The impact of genetics on future drug discovery in schizophrenia.

Matsumoto M, Walton NM, Yamada H, Kondo Y, Marek GJ, Tajinda K. Matsumoto M, et al. Among authors: marek gj. Expert Opin Drug Discov. 2017 Jul;12(7):673-686. doi: 10.1080/17460441.2017.1324419. Epub 2017 May 18. Expert Opin Drug Discov. 2017. PMID: 28521526 Review.

Cite

Share

5

Cite

Share

Cortical influences of serotonin and glutamate on layer V pyramidal neurons.

Marek GJ, Schoepp DD. Marek GJ, et al. Prog Brain Res. 2021;261:341-378. doi: 10.1016/bs.pbr.2020.11.002. Epub 2021 Jan 14. Prog Brain Res. 2021. PMID: 33785135

Cite

Share

6

Cite

Share

Metabotropic glutamate2/3 (mGlu2/3) receptors, schizophrenia and cognition.

Marek GJ. Marek GJ. Eur J Pharmacol. 2010 Aug 10;639(1-3):81-90. doi: 10.1016/j.ejphar.2010.02.058. Epub 2010 Apr 2. Eur J Pharmacol. 2010. PMID: 20371229 Review.

Cite

Share

7

Cite

Share

Pharmacokinetics of ASP4345 from Single Ascending-Dose and Multiple Ascending-Dose Phase I Studies.

Desai A, Benner L, Wu R, Gertsik L, Uz T, Marek GJ, Zhu T. Desai A, et al. Among authors: marek gj. Clin Pharmacokinet. 2021 Jan;60(1):79-88. doi: 10.1007/s40262-020-00911-0. Clin Pharmacokinet. 2021. PMID: 32533536 Free PMC article.

Cite

Share

8

Cite

Share

A randomized phase 1 single-dose polysomnography study of ASP8062, a GABA_B receptor positive allosteric modulator.

Walzer M, Wu R, Ahmad M, Freeman J, Zammit G, Marek GJ. Walzer M, et al. Among authors: marek gj. Psychopharmacology (Berl). 2021 Mar;238(3):867-876. doi: 10.1007/s00213-020-05738-y. Epub 2021 Jan 12. Psychopharmacology (Berl). 2021. PMID: 33433644 Free PMC article. Clinical Trial.

Cite

Share

9

Cite

Share

Metabotropic glutamate receptors in the control of mood disorders.

Witkin JM, Marek GJ, Johnson BG, Schoepp DD. Witkin JM, et al. Among authors: marek gj. CNS Neurol Disord Drug Targets. 2007 Apr;6(2):87-100. doi: 10.2174/187152707780363302. CNS Neurol Disord Drug Targets. 2007. PMID: 17430147 Review.

Cite

Share

10

Cite

Share

Phase 1 randomized study on the safety, tolerability, and pharmacodynamic cognitive and electrophysiological effects of a dopamine D₁ receptor positive allosteric modulator in patients with schizophrenia.

Desai A, Benner L, Wu R, Gertsik L, Maruff P, Light GA, Uz T, Marek GJ, Zhu T. Desai A, et al. Among authors: marek gj. Neuropsychopharmacology. 2021 May;46(6):1145-1151. doi: 10.1038/s41386-020-00908-0. Epub 2020 Nov 17. Neuropsychopharmacology. 2021. PMID: 33203954 Free PMC article. Clinical Trial.

Cite

Share